A5031405616- Sarcoma Diagnosis and Treatment
- Head and Neck Cancer Studies
- Vascular Tumors and Angiosarcomas
- Protein Degradation and Inhibitors
- Cancer-related gene regulation
- CAR-T cell therapy research
- Cardiac tumors and thrombi
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Salivary Gland Tumors Diagnosis and Treatment
- Gastrointestinal Tumor Research and Treatment
- Lung Cancer Treatments and Mutations
- Cancer Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Ear and Head Tumors
- Gastric Cancer Management and Outcomes
- Cancer Mechanisms and Therapy
- Peptidase Inhibition and Analysis
- Cancer Genomics and Diagnostics
- Head and Neck Surgical Oncology
- Colorectal Cancer Treatments and Studies
- Chromatin Remodeling and Cancer
- Cancer Immunotherapy and Biomarkers
- Neuroblastoma Research and Treatments
- Cancer Research and Treatments
City Of Hope National Medical Center
2021-2025
City of Hope
2014-2025
University of Southern California
2025
Keck Hospital of USC
2024
University of California, San Diego
2023
Yahoo (United Kingdom)
2023
Northwestern University
2013-2022
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2007-2021
Northwestern Memorial Hospital
2009-2019
Chinese University of Hong Kong
2018
Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, other connective tissues. The evaluation treatment patients with requires multidisciplinary team demonstrated expertise in the management these tumors. complete NCCN Clinical Practice Guidelines Oncology (NCCN Guidelines) for Tissue Sarcoma provide recommendations diagnosis, evaluation,...
Purpose Induction chemotherapy (IC) before radiotherapy lowers distant failure (DF) rates in locally advanced squamous cell carcinoma of the head and neck (SCCHN). The goal this phase III trial was to determine whether IC chemoradiotherapy (CRT) further improves survival compared with CRT alone patients N2 or N3 disease. Patients Methods Treatment-naive nonmetastatic SCCHN were randomly assigned (CRT arm; docetaxel, fluorouracil, hydroxyurea plus 0.15 Gy twice per day every other week)...
Purpose This multinational study evaluated the antitumor activity of nivolumab in nasopharyngeal carcinoma (NPC). Tumor and plasma-based biomarkers were investigated an exploratory analysis. Patients Methods with multiply pretreated recurrent or metastatic NPC treated until disease progression. The primary end point was objective response rate (ORR) secondary points included survival toxicity. expression programmed death-ligand 1 (PD-L1) human leukocyte antigens A B archived tumors plasma...
To determine efficacy and safety of bevacizumab, a recombinant humanized antibody against vascular endothelial growth factor (VEGF), in the treatment metastatic or locally advanced angiosarcoma epithelioid hemangioendotheliomas.In this single-arm phase II trial, 32 patients were enrolled they received bevacizumab 15 mg/kg IV infusion 21-day cycles. Patients had disease that was deemed not surgically resectable, Eastern Cooperative Oncology Group (ECOG) performance status ≤1, adequate organ...
The NCCN Guidelines for Bone Cancer provide interdisciplinary recommendations treating chordoma, chondrosarcoma, giant cell tumor of bone, Ewing sarcoma, and osteosarcoma. These Insights summarize the Panel's guideline sarcoma. data underlying these treatment are also discussed.
PURPOSE SARC024 is a phase II clinical trial of the multikinase inhibitor regorafenib in specific sarcoma subtypes, including advanced osteosarcoma. We hypothesized that would improve progression-free survival (PFS) patients with and report results osteosarcoma cohort. PATIENTS AND METHODS This enrolled progressive metastatic measurable disease by RECIST who had received at least one prior line therapy. Patients were randomly assigned ratio to or placebo. Crossover was allowed time...
Purpose Palifosfamide is the active metabolite of ifosfamide and does not require prodrug activation, thereby avoiding generation toxic metabolites. The PICASSO III trial compared doxorubicin plus palifosfamide with placebo in patients who had received no prior systemic therapy for metastatic soft tissue sarcoma. Patients Methods were randomly assigned 1:1 to receive 75 mg/m2 intravenously day 1 150 mg/m2/d days 3 or once every 21 up six cycles. primary end point was progression-free...
Purpose Angiosarcoma is a rare aggressive endothelial cell cancer with high mortality. Isolated reports suggest immune checkpoint inhibition efficacy in angiosarcoma, but no prospective studies have been published. We report results for angiosarcoma treated ipilimumab and nivolumab as cohort of an ongoing study. Methods This prospective, open-label, multicenter phase II clinical trial (1 mg/kg intravenously every 6 weeks) plus (240 mg 2 metastatic or unresectable angiosarcoma. Primary...
Abstract There are more than 70 distinct sarcomas, and this diversity complicates the development of precision-based therapeutics for these cancers. Prospective comprehensive genomic profiling could overcome challenge by providing insight into sarcomas’ molecular drivers. Through targeted panel sequencing 7494 sarcomas representing 44 histologies, we identify highly recurrent type-specific alterations that aid in diagnosis treatment decisions. Sequencing lead to refinement or reassignment...
PURPOSE Outcomes for patients with advanced sarcomas are poor and there is a high unmet need to develop novel therapies. The purpose of this phase I study was define the safety efficacy botensilimab (BOT), an Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody, plus balstilimab (BAL), anti–PD-1 in sarcomas. METHODS BOT administered intravenously (IV) at 1 mg/kg or 2 once every 6 weeks combination BAL IV 3 up years. primary end point determine dose-limiting toxicities during...
Expression of erbB2 and/or epidermal growth factor receptor (EGFR) is associated with biologic aggressiveness and poor prognosis in malignant salivary gland tumors (MSGTs). This phase II study was conducted to determine the antitumor activity lapatinib, a dual inhibitor EGFR tyrosine kinase activity, MSGTs.Patients progressive, recurrent, or metastatic adenoid cystic carcinoma (ACC) immunohistochemically expressing at least 1+ 2+ were treated lapatinib 1,500 mg daily, two-stage cohort....
Purpose To determine the efficacy and safety of single-agent sorafenib in patients with recurrent and/or metastatic squamous cell carcinoma head neck (SCCHN) nasopharyngeal (NPC). Patients Methods In this single-arm phase II trial, oral continuous was administered 28-day cycles. had ≤ one line chemotherapy for disease, Eastern Cooperative Oncology Group performance status 2, adequate organ function. At end stage 1, criteria further accrual were not met, but study amended to enroll an...
Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-like growth factor-1 receptor (IGF-1R) and mTOR. The expression IGF-1R seems to be crucial for this effect. We investigated the safety efficacy combination antibody cixutumumab mTOR inhibitor temsirolimus in patients with chemotherapy-refractory bone soft-tissue sarcomas according immunohistochemistry.We undertook a multicentre, open-label, phase 2 study 19 cancer centres USA. Patients aged at least 16...
Patients treated with epidermal growth factor receptor inhibitors (EGFRIs) frequently experience dermatologic toxic effects. Whereas the impact of these effects on quality life and EGFRI dosing has been described, their physical health not ascertained. We examined prevalence infections that complicate EGFRIs.We used retrospective chart review methods to analyze 221 patients who were in Skin Eye Reactions Inhibitors EGFR Kinases clinic, a referral clinic for cancer therapies. reviewed results...
Abstract BACKGROUND. Few studies have examined the costs of supportive care for radiochemotherapy‐induced mucosits/pharyngitis among patients with head and neck cancer (HNC) or lung cancers despite documented negative clinical impact these complications. METHODS. The authors identified a retrospective cohort HNC nonsmall (NSCLC) who had received radiochemotherapy at 1 3 Chicago hospitals (a Veterans Administration hospital, county tertiary hospital). Charts were reviewed presence/absence...
5500 Background: IC is associated with lower distant failure (DF) rates in SCCHN but an improvement overall survival (OS) has not been validated. The goal of this trial was to determine whether prior chemoradiotherapy (CRT) improves compared CRT alone. Methods: In phase 3, open-label trial, subjects pathologically confirmed SCCHN; N2/N3 disease without metastases; no therapy; KPS ³ 70%; and intact organ function were randomized alone (CRT arm) [5 days D (25 mg/m 2 ), F (600 hydroxyurea (500...
Primary bone cancers are extremely rare neoplasms, accounting for fewer than 0.2% of all cancers. The evaluation and treatment patients with requires a multidisciplinary team physicians, including musculoskeletal, medical, radiation oncologists, surgeons radiologists demonstrated expertise in the management these tumors. Long-term surveillance follow-up necessary late effects related to surgery, therapy, chemotherapy. These guidelines discuss chordoma, giant cell tumor bone, osteosarcoma.
The discovery of epidermal growth-factor receptor (EGFR)-activating mutations and the introduction oral EGFR tyrosine kinase inhibitors (EGFR-TKIs) have expanded treatment options for patients with non-small cell lung cancer. first two reversible EGFR-TKIs, erlotinib gefitinib, are approved use in first-line setting known EGFR-activating second- third-line settings all NSCLC patients. These first-generation EGFR-TKIs improve progression-free survival when compared to chemotherapy setting....